MODD · XBRL financial data
Modular Medical financial statements, every fiscal year
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (MODD's year ends in late March)
| In millions of dollars | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 | Mar 31, 2025 | †Mar 31, 2026 |
|---|---|---|---|---|---|---|
| Research and development | 4 | 8 | 9 | 13 | 15 | 20 |
| General and administrative | 3 | 7 | 5 | 5 | 4 | 8 |
| Total operating expenses | 7 | 15 | 14 | 18 | 19 | 28 |
| Operating income (loss) | (7) | (15) | (14) | (18) | (19) | (28) |
| Interest expense | (0) | 3 | — | — | — | — |
| Income tax expense (benefit) | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income (loss) | (7) | (19) | (14) | (17) | (19) | (28) |
| Earnings per share, basic USD per share | — | (2.74) | (1.28) | (0.78) | (0.51) | (12.36) |
| Earnings per share, diluted USD per share | — | (2.74) | (1.28) | (0.78) | (0.51) | (12.36) |
| Weighted average shares, basic millions of shares | — | 7 | 11 | 22 | 37 | 2 |
| Weighted average shares, diluted millions of shares | — | 7 | 11 | 22 | 37 | 2 |
- † Share count changed about 100x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (MODD's year ends in late March)
| In millions of dollars | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 | Mar 31, 2025 | †Mar 31, 2026 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 1 | 9 | 4 | 9 | 13 | 7 |
| Prepaid and other current assets | — | 0 | 0 | 0 | 0 | 1 |
| Total current assets | 2 | 9 | 4 | 10 | 14 | 8 |
| Property and equipment, net | 0 | 0 | 2 | 3 | 4 | 7 |
| Right-of-use asset | 0 | 0 | 1 | 1 | 1 | 0 |
| Total assets | 2 | 10 | 7 | 14 | 19 | 15 |
| Accounts payable | — | 0 | 0 | 1 | 0 | 1 |
| Accrued liabilities | — | 1 | 0 | 0 | 1 | 0 |
| Total current liabilities | 3 | 1 | 1 | 1 | 1 | 2 |
| Lease liability, non-current | 0 | 0 | 1 | 1 | 0 | — |
| Total liabilities | 4 | 1 | 2 | 2 | 2 | 2 |
| Accumulated deficit | (16) | (35) | (48) | (66) | (85) | (113) |
| Total stockholders' equity | (1) | 9 | 5 | 12 | 17 | 13 |
| Total liabilities and equity | 2 | 10 | 7 | 14 | 19 | 15 |
| Common shares outstanding (cover page) millions of shares | 19 | 11 | 21 | 33 | 54 | 5,413 |
- † Share count changed about 100x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (MODD's year ends in late March)
| In millions of dollars | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 | Mar 31, 2025 | †Mar 31, 2026 |
|---|---|---|---|---|---|---|
| Net income (loss) | (7) | (19) | (14) | (17) | (19) | (28) |
| Stock-based compensation | 1 | 4 | 3 | 3 | 2 | 2 |
| Net cash from operating activities | (6) | (10) | (11) | (14) | (16) | (24) |
| Purchases of property and equipment | 0 | 0 | 2 | 2 | 2 | 4 |
| Net cash from investing activities | (0) | (0) | (2) | (2) | (2) | (4) |
| Proceeds from issuing common stock | — | — | — | 0 | 2 | 16 |
| Net cash from financing activities | 4 | 18 | 7 | 21 | 22 | 22 |
| Net change in cash | (2) | 8 | (5) | — | — | — |
- † Share count changed about 100x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Modular Medical | 3.9 | not reported | (6) | 8.2M | 0.7 quarters | 10-QJun 30, 2026 |
| HeartBeam | 8.7 | not reported | (3.3)* | 56.3M | 2.6 quarters | 10-QJun 30, 2026 |
| Vicarious Surgical | 1.4 | not reported | (6.3) | not reported | 0.6 quarters | 10-QMar 31, 2026 |
| Milestone Scientific | 2.1 | not reported | (0.6)* | 88.7M | 3.5 quarters | 10-QJun 30, 2026 |
| Nuo Therapeutics | 0.4 | not reported | (0.2)* | 48.4M | 1.9 quarters | 10-QJun 30, 2026 |
| Alpha Pro Tech | 19 | not reported | 2.2* | 10.2M | — | 10-QJun 30, 2026 |
| QT Imaging Holdings | 11 | 7.4 | (4.8)* | 14.6M | 2.3 quarters | 10-QJun 30, 2026 |
| Cerenome | 2.4 | 0.4 | (7.1)* | 7.6M | 1.2 quarters | 10-QJun 30, 2026 |
| Hyperfine | 43 | 3.9 | (7.3)* | not reported | 6.0 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.